title: [Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors in CKD].
abstract: Among the new drugs used for the treatment of Diabetes Mellitus type 2, sodium-glucose cotransporter 2 (SGLT2) inhibitors represent a promising therapeutic option. Since their ability to lower glucose is proportional to GFR, their effect is reduced in patients with chronic kidney disease (CKD). The antidiabetic mechanism of these drugs is insulin-independent and, therefore, complimentary to that of others antihyperglicaemic agents. Moreover, SGLT2 inhibitors are able to reduce glomerular hyperfiltration, systemic and intraglomerular pressure and uric acid levels, with consequent beneficial effects on the progression of kidney disease in non diabetic patients as well. Only few studies have been performed to evaluate the effects of SGLT2 inhibitors in patients with CKD. Therefore, safety and efficacy of SGLT2 inhibitors should be better clarified in the setting of CKD. In this paper, we will review the use of SGLT2 inhibitors in diabetic patients, including those with CKD.
authors.forename: Monica
authors.initials: M
authors.lastname: Insalaco
authors.forename: Luca
authors.initials: L
authors.lastname: Zanoli
authors.forename: Stefania
authors.initials: S
authors.lastname: Rastelli
authors.forename: Paolo
authors.initials: P
authors.lastname: Lentini
authors.forename: Francesco
authors.initials: F
authors.lastname: Rapisarda
authors.forename: Pasquale
authors.initials: P
authors.lastname: Fatuzzo
authors.forename: Pietro
authors.initials: P
authors.lastname: Castellino
authors.forename: Antonio
authors.initials: A
authors.lastname: Granata
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D051436:Renal Insufficiency, Chronic / Q000150:complications*; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors
chemical_list: D007004:Hypoglycemic Agents; C089180:SLC5A2 protein, human; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors